Guidelines: Ros1+ NSCLC
Guidelines: Ros1+ NSCLC
An expert highlights the evolution of ROS1-positive non-small cell lung cancer care, emphasizing early RNA-based molecular testing, the 2025 NCCN guideline shift to next-generation TKIs like talotrectinib and repotrectinib, and the need to avoid immunotherapy in favor of personalized, targeted treatment despite challenges in trial access and disease rarity.
Recognizing and Testing for ROS1 in NSCLC
September 10th 2025An expert discusses the evolution of ROS1 testing in non-small cell lung cancer, highlighting the shift from FISH-based methods to comprehensive next-generation sequencing of both tissue and plasma, emphasizing RNA-based assays for detecting gene fusions, and stressing the importance of early molecular testing to guide targeted therapy selection and improve patient outcomes.
Read More
